GlassScriptPhysician profile
Lyla M Prather
NPI 1386721009
$28,950.14
in general payments reported to CMS, 2019-2025
40 companies · $2,978 in 2025
The $2,978 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,722 · 2020: $2,672 · 2021: $3,258 · 2022: $6,464 · 2023: $5,709 · 2024: $3,148 · 2025: $2,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Honoraria: $875 · Travel and Lodging: $92.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,867.62 |
| Honoraria | $875.00 |
| Travel and Lodging | $92.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $8,813.75 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $3,045.31 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $2,314.26 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $2,268.53 | 2021-2025 | |
| Glaxosmithkline, LLC. | $2,160.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,981.12 | 2021-2025 | |
| Lilly USA, LLC | $1,006.92 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $849.94 | 2019-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $813.88 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $632.75 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Merck Sharp & Dohme LLC | $491.83 | 2020-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Novo Nordisk INC | $449.75 | 2021-2023 | Wegovy |
| Janssen Pharmaceuticals, INC | $442.05 | 2019-2023 | Xarelto |
| Pfizer INC. | $398.82 | 2019-2025 | |
| Esperion Therapeutics, INC. | $339.04 | 2020-2025 | Nexletol |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyla Prather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.